Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Office of Personnel Management

Executive Summary

Pfizer, Merck and Parke-Davis (now part of Pfizer) refused to supply pharmaceuticals at Federal Supply Schedule prices for Special Agents Mutual Benefit Association Health Plan mail-order prescriptions, resulting in OMB calling off the pilot project. Started in June, the goal of the pilot program was to determine whether FSS prices should be extended to all Federal Employee Health Benefits Program plans (1"The Pink Sheet" June 19, p. 13). Merck-Medco is the pharmacy benefit management company that administers the SAMBA plan
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS036632

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel